Haemonetics Corporation HAE

Company Overview

Haemonetics Corporation is a U.S.-based medical technology company that develops and provides products, software, and services focused on blood and plasma collection, hospital transfusion management, and hemostasis management. The company operates primarily within the healthcare technology and medical devices industries, serving blood centers, plasma collection organizations, hospitals, and surgical care providers. Its core revenue drivers include plasma collection systems, blood management technologies, hospital software platforms, and hemostatic management solutions used in surgical and critical care environments.

The company was founded in 1971 and is headquartered in Boston, Massachusetts. Haemonetics initially built its business around automated blood collection technologies and expanded over time into plasma collection systems, hospital transfusion software, and cardiovascular and surgical technologies through internal development and acquisitions. The company has established a strong market position in plasma collection, supported by long-standing relationships with major plasma collection operators and integrated technology platforms that combine devices, disposables, and software analytics.

Business Operations

Haemonetics organizes its operations primarily across the Plasma, Blood Center, and Hospital business segments. The Plasma segment is a major contributor to revenue and includes automated plasma collection systems, software, and disposables used by plasma collection centers. The Blood Center segment provides whole blood and component collection technologies for blood banks and donation centers. The Hospital segment includes technologies and software for transfusion management, cell salvage, hemostasis diagnostics, and cardiovascular procedure management. Revenue is generated through both capital equipment sales and recurring consumable and software-related revenue streams.

The company maintains operations across the United States, Europe, Asia-Pacific, and other international markets. Haemonetics controls proprietary apheresis technologies, blood management software, and surgical care platforms. Important assets include its installed base of collection devices and recurring consumables business model. Key subsidiaries and acquired businesses include Vascade, Cardiva Medical, and technologies obtained through the acquisition of Attune Medical. The company also collaborates with large plasma collection organizations and healthcare systems to integrate workflow software and data-driven operational tools.

Strategic Position & Investments

Haemonetics has focused its strategic direction on expanding higher-growth and higher-margin businesses, particularly plasma collection technologies and hospital-based hemostasis management solutions. The company has invested in software-enabled healthcare technologies and procedural solutions designed to improve efficiency, patient outcomes, and donor yield optimization. Strategic priorities outlined in public filings and investor communications have included innovation in plasma collection automation, hospital workflow digitization, and expansion of interventional cardiovascular technologies.

The company has completed several acquisitions to strengthen its hospital and vascular closure portfolios. Notable transactions include the acquisitions of Cardiva Medical, which added vascular closure technologies, and Attune Medical, which expanded the company’s temperature management capabilities. Haemonetics has also invested in data analytics and connected-device infrastructure to support operational decision-making for plasma collection customers. Its positioning in the plasma market benefits from increasing global demand for plasma-derived therapies and from long-term customer relationships with large collection network operators.

Geographic Footprint

Haemonetics operates globally, with its headquarters located in Boston, Massachusetts and business activities spanning North America, Europe, Asia-Pacific, Latin America, and parts of the Middle East. The company maintains manufacturing, research, sales, and service operations in multiple countries to support healthcare providers, blood centers, and plasma collection organizations. The United States remains its largest market, particularly due to the scale of the domestic plasma collection industry.

Internationally, the company serves healthcare systems and blood management organizations across developed and emerging markets. Its technologies are used in hospitals and collection centers throughout Europe and selected countries in Asia-Pacific, where demand for blood management and plasma collection infrastructure continues to grow. Haemonetics’ global operational footprint supports both direct sales and distributor-based market access strategies depending on the region.

Leadership & Governance

Haemonetics is governed by a board of directors and executive leadership team with experience across medical devices, healthcare technology, operations, and finance. The company’s leadership strategy has emphasized portfolio optimization, recurring revenue growth, operational efficiency, and expansion into higher-growth medical technology categories. Public company governance practices are guided through disclosures in SEC filings, annual reports, and investor presentations.

Key executives include:

• Christopher Simon – President and Chief Executive Officer
• William Burke – Executive Vice President, Chief Financial Officer
• Stewart Strong – President, Global Hospital
• Kathleen Noonan – Executive Vice President, Chief Legal Officer and Secretary
• Dan Goldberger – Former President and Chief Executive Officer associated with prior strategic expansion initiatives

Information above is based on publicly available company disclosures, including SEC filings, annual reports, investor materials, and major financial and industry publications. Where executive transitions or segment reporting changes may vary across reporting periods, data reflects the most consistently verified public information available.